Share this Page:
Results from a phase 2 study to assess the activity of axitinib in patients with metastatic renal cell carcinoma (RCC) with a favourable risk (FavorAx) after having received first-line treatment with a vascular endothelial growth factor receptor (VEGFR)-directed therapy.
In this study, median progression-free survival was 19 months, and the study achieved its primary endpoint based on 100% of patients surviving 5 months without disease progression. There was no discontinuation of treatment due to adverse events.
Results from the FavorAx study support the administration of axitinib to metastatic RCC patients with favourable risk in the second-line following first-line treatment with sunitinib or pazopanib.